Serotype Replacement in Childhood Invasive Pneumococcal Disease
Understanding the pneumococcal population dynamics will drive an effective next-generation vaccine design.
Pneumonia
Molecular Methods Show PCV Vaccine May Reduce Colony Density, Not Acquisition
The PCV-13 demonstrated an association with the detection of low-density colonization and resulted in vaccine efficacy against colonization acquisition.
Simvastatin May Improve In-Hospital Survival in Pneumonia With Sepsis
In elderly patients who are admitted to the hospital with community-acquired pneumonia with sepsis and do not require critical care unit support, the use of high-dose simvastatin may improve clinical outcomes.
Medicare Advantage Patients Have Higher Readmission Rates
Higher adjusted readmission rates seen for acute MI, congestive heart failure, and pneumonia with Medicare Advantage,
Testing and Antibiotic Use in Children With Community-Acquired Pneumonia
Despite national guideline recommendations and the high prevalence of viral etiology of CAP in children, the use of antibiotics remains high.
Pulmonary Complications Linked to High-Dose Naloxone for Opioid Overdose
Higher rates of pulmonary complications are more likely to occur in patients who receive high total doses of naloxone for the treatment of opioid overdose in an out-of-hospital setting.
Delafloxacin Gets FDA’s Priority Review for Community-Acquired Bacterial Pneumonia
The FDA has accepted for priority review the supplemental New Drug Application for Baxdela for CABP.
Resistant Organisms in Community-Acquired Pneumonia With or Without Alcohol Use Disorders
Hospitalized patients with community-acquired pneumonia and alcohol use disorder harbor resistant organisms less frequently than patients without alcohol use disorder.
Treatment Options for Methicillin-Resistant Staphylococcus Aureus Pneumonia Evaluated
Evidence for the treatment of MRSA pneumonia with trimethoprim-sulfamethoxazole, clindamycin, doxycycline, or minocycline was found to be based on limited data.
Ceftolozane and Tazobactam Approved to Treat Hospital-Acquired and Ventilator-Associated Pneumonia
The FDA has expanded the approval of Zerbaxa to include treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in pediatric patients.
Next post in Pneumonia
